RLBP1 Antibody

Code CSB-PA019743LA01HU
Size US$166
Order now
Image
  • Immunohistochemistry of paraffin-embedded human eye tissue using CSB-PA019743LA01HU at dilution of 1:100

  • Immunofluorescent analysis of HepG2 cells using CSB-PA019743LA01HU at dilution of 1:100 and Cy3-congugated Goat Anti-Rabbit IgG

The Latest Promotion Free Antibody trial simple
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) RLBP1 Polyclonal antibody
Uniprot No.
Target Names
RLBP1
Alternative Names
Cellular retinaldehyde binding protein 1 antibody; Cellular retinaldehyde binding protein antibody; Cellular retinaldehyde-binding protein antibody; MGC3663 antibody; Retinaldehyde binding protein 1 antibody; Retinaldehyde-binding protein 1 antibody; RLBP 1 antibody; RLBP1 antibody; RLBP1_HUMAN antibody
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Recombinant Human Retinaldehyde-binding protein 1 protein (10-91AA)
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated

The RLBP1 Antibody (Product code: CSB-PA019743LA01HU) is Non-conjugated. For RLBP1 Antibody with conjugates, please check the following table.

Available Conjugates
Conjugate Product Code Product Name Application
HRP CSB-PA019743LB01HU RLBP1 Antibody, HRP conjugated ELISA
FITC CSB-PA019743LC01HU RLBP1 Antibody, FITC conjugated
Biotin CSB-PA019743LD01HU RLBP1 Antibody, Biotin conjugated ELISA
Clonality
Polyclonal
Isotype
IgG
Purification Method
>95%, Protein G purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Tested Applications
ELISA, IHC, IF
Recommended Dilution
Application Recommended Dilution
IHC 1:20-1:200
IF 1:50-1:200
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Soluble retinoid carrier essential the proper function of both rod and cone photoreceptors. Participates in the regeneration of active 11-cis-retinol and 11-cis-retinaldehyde, from the inactive 11-trans products of the rhodopsin photocycle and in the de novo synthesis of these retinoids from 11-trans metabolic precursors. The cycling of retinoids between photoreceptor and adjacent pigment epithelium cells is known as the 'visual cycle'.
Gene References into Functions
  1. RLBP1 gene geographical area-related mutation is associated with retinitis punctata albescens. PMID: 28764803
  2. we provide evidence for an allosteric modulation of the enzymatic activity by 11-cis retinoids. This regulation is independent from cellular retinaldehyde-binding protein (CRALBP), the major cis-retinoid binding protein. PMID: 28096191
  3. These results show that joint tests of main effects and gene-gene interaction reveal associations at some novel loci that were missed when considering main effects alone. PMID: 28813576
  4. Different mutations in RLBP1 are correlated with quite different morphological and functional characteristics outlines the complexity of the protein. PMID: 25429852
  5. RLBP1 gene is upregulated in patients with reactive retinal astrocytic tumors. PMID: 24921169
  6. Patients with retinitis punctata albescens (RPA) show variable degrees of foveal cone death, even at an early stage. This finding has implications for future treatment. PMID: 23929416
  7. The two RLBP1 genotypes presented a phenotypical and electrophysiological expression of progressive retinal disease similar to that previously described in homozygotes for the c.700C>T (p.R234W) RLBP1 mutation. PMID: 22551409
  8. The clinical characteristics of a Japanese patient with a homozygous R234W mutation in RLBP1 are very similar to that of Swedish patients with Bothnia dystrophy. PMID: 22171637
  9. Identification of autoantibodies specific for two retinal antigens (CRALBP and S-Ag) supports the concept of an autoimmunological origin of the disease. PMID: 21904838
  10. The R234W mutation reveals impaired 11-cis-retinal release through stabilization of the ligand complex. PMID: 22183382
  11. mutations in RLBP1 are responsible for fundus albipunctatus in the affected individuals of these consanguineous Pakistani families. PMID: 21447491
  12. In the RLBP1-Bothnia dystrophy phenotype, a loss of function and thinning of the central macula are found, indicating early damage of the cone photoreceptors in this disease of the visual cycle. PMID: 20696998
  13. Newfoundland rod-cone dystrophy, an early-onset retinal dystrophy, is caused by splice-junction mutations in RLBP1 PMID: 11868161
  14. the M225K mutation abolishes and the R233W mutation tightens retinoid binding and both impair CRALBP function in the visual cycle as an 11-cis-retinol acceptor and as a substrate carrier. PMID: 12536144
  15. Trp-165, Met-208, Met-222, Met-225, and Trp-244 are components of the CRALBP ligand binding cavity. PMID: 12536149
  16. Patients with a clinical presentation of RPA (retinitis punctata albescens) can have genetically different mutations. PMID: 14718298
  17. Only eight RLBP1 mutations have been reported to date, and here we describe two novel mutations. PMID: 15234312
  18. Cellular retinaldehyde binding protein 1 (CRALBP) inhibits the reduction of 11-cis-retinal stronger than the oxidation of 11-cis-retinol, in accord with its higher affinity for 11-cis-retinal. PMID: 15865448
  19. A novel mutation in RLBP1 gene was found in a Japanese patient with retinitis punctata albescens. Degenerative changes of the outer retina were detected by optical coherence tomography PMID: 15953459
  20. Because of the high density of Alu elements in RLBP1, a systematic search should be made for deletions in this gene when one or both alleles lack point mutations, in the case of RPA or flecked retinal dystrophy. PMID: 17065479
  21. analysis of CRALBP ligand and protein interactions PMID: 17249612
  22. CRALBP transcripts in retinal pigment epithelium cells contain a noncoding exon in addition to a newly described promoter and, by definition, an additional intron PMID: 17652763
  23. The presence of CRALBP autoantibodies in 54% of tested uveitis patients supports CRALBP as a possible autoantigen in human autoimmune uveitis PMID: 18317528
  24. Bothnia dystrophy is caused by the loss of CRALBP function due to changed physical features and impaired activity of retinoid binding. PMID: 18344446
  25. These results reveal an unanticipated domino-like structural transition causing Bothnia-type retinal dystrophy by the impaired release of 11-cis-retinal from R234W. PMID: 19846785
  26. Using shotgun mass spectrometry, we found this protein differentially expressed in the dorsolateral prefrontal cortex from patients with schizophrenia PMID: 19165527

Show More

Hide All

Involvement in disease
Bothnia retinal dystrophy (BRD); Rod-cone dystrophy Newfoundland (NFRCD); Retinitis punctata albescens (RPA)
Subcellular Location
Cytoplasm.
Tissue Specificity
Retina and pineal gland. Not present in photoreceptor cells but is expressed abundantly in the adjacent retinal pigment epithelium (RPE) and in the Mueller glial cells of the retina.
Database Links

HGNC: 10024

OMIM: 136880

KEGG: hsa:6017

STRING: 9606.ENSP00000268125

UniGene: Hs.1933

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*